Illustrative image – not actual.MSD Pharmaceuticals, a wholly-owned subsidiary of Merck Sharp & Dohme (MSD), has inked a pact with Indian generic manufacturers -- Sun Pharmaceutical Industries, Cipla, Dr Reddy’s Laboratories, Emcure Pharmaceuticals and Hetero Labs -- to contract manufacture the COVID-19 drug Molnupiravir.
The agreements are aimed at accelerating availability of Molnupiravir in India and in other low- and middle-income countries (LMICs) following approvals or emergency authorisation by local regulatory agencies. The company will soon approach the Drugs Controller General of India for a regulatory authorisation.
MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics. Under the agreements, Merck & Company will provide licenses to these manufacturers to supply Molnupiravir to India and more than 100 LMICs.
The agreements are aimed at accelerating availability of Molnupiravir in India and in other low- and middle-income countries (LMICs) following approvals or emergency authorisation by local regulatory agencies. The company will soon approach the Drugs Controller General of India for a regulatory authorisation.
MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics. Under the agreements, Merck & Company will provide licenses to these manufacturers to supply Molnupiravir to India and more than 100 LMICs.
